About the NASH Council

The purpose of the NASH Council is to shine a spotlight and coalesce an expanded set of stakeholders, in addition to hepatology, around the urgency of developing mechanisms for quantifying and addressing the silent epidemic of fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in the U.S. and abroad. Current estimates are that as many as 1 in 4 people already have NAFLD or NASH yet these conditions are underrecognized, underdiagnosed, and undertreated.

GLI's NASH Collaborations

TARGET-NASH Observational Study

TARGET PharmaSolutions is a data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting. TARGET PharmaSolutions has announced it’s long-term strategic alliance for TARGET-NASH which originally launched August 2016. TARGET-NASH is a longitudinal observational study that evaluates adults and pediatric patients with NAFLD or NASH. The academic steering committee is chaired by Dr. Arun Sanyal, Dr. Ken Cusi, and Dr. Brent Tetri.

NASH Education Program

In order to address unmet needs related to this disease that deserves a wider exposure, GENFIT has begun to lead a public health initiative title the NASH Education Program, aimed at producing and disseminating essential medical knowledge toward a targeted audience.

NASH Summit

April 3-5, 2019 | Boston, MA

Join 150+ drug developers from 120+ organizations at this focused discussion and networking forum and gain actionable insights to accelerate the development of your NASH therapeutic pipeline.

The Liver Forum

The Liver Forum is an initiative of the Forum for Collaborative Research, part of the University of California, Berkeley School of Public Health. The Liver Forum was launched in 2014 in response to The Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease (NAFLD) meeting sponsored in 2013 by the U.S. Food and Drug Administration (FDA) and the American Association for the Study of Liver Disease (AASLD).

The Liver Forum aims to advance the regulatory sciences for the treatment of Non-Alcoholic Steatohepatitis and liver fibrosis by providing an independent and neutral venue for ongoing multi-stakeholder dialogue to identify and address gaps in the field. Neutrality and objectivity is ensured through representation and active engagement of scientific experts from all stakeholder groups, including academia, industry, patient community and regulatory agencies.

GLI President and CEO Donna R. Cryer, JD is included in this expert group of stakeholders on the steering committee as a community representative.

GLI NASH Resources


NASH Council Members

Want to be a member? Membership Application Form

  • Allergan

  • American Association of Clinical Endocrinologists

  • American Association for the Study of Liver Diseases

  • American College of Physicians

  • American Gastroenterological Association

  • American Heart Association

  • Amsety

  • Apollo Endosurgery, Inc.

  • blackdoctor.org

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Cancer and Chronic Disease Prevention: DC Department of Health

  • Celgene

  • Duke University School of Medicine

  • Endocrine Society

  • European Liver Patients Association

  • Fatty Liver Foundation

  • Food & Drug Administration

  • Gartman PR

  • Genfit

  • George Washington University - Milken Institute School of Public Health

  • Gilead Sciences, Inc.

  • Intercept Pharmaceuticals

  • Joslin Diabetes Center

  • The Liver Forum

  • Massachusetts General Hospital/Harvard Medical School: Fatty Liver Disease Clinic

  • McGuire VA Medical Center

  • Medical University of South Carolina

  • Metabolys Inc.

  • NASH kNOWledge

  • National Center for Weight and Wellness/Obesity Society

  • National Hispanic Medical Association

  • Nestle Health Science

  • Northwestern University

  • Novo Nordisk, Inc.

  • Obesity Action Campaign

  • Perspectum Diagnostics

  • Pfizer Inc.

  • Physicians Committee for Responsible Medicine

  • Preventive Cardiovascular Nurses Association

  • Rush University

  • Rutgers University

  • Tampa General Medical Group/ USF Tampa

  • Target-NASH PharmaSolutions

  • University of California San Francisco Medical Center

  • University of Michigan NAFLD Clinic

  • Virginia Commonwealth University School of Medicine